Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival-Reference-Cited by-同舟云学术

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Published:2017-02-02 Issue:6 Volume:109 Page:
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Lee Chee Khoon,Davies Lucy,Wu Yi-Long,Mitsudomi Tetsuya,Inoue Akira,Rosell Rafael,Zhou Caicun,Nakagawa Kazuhiko,Thongprasert Sumitra,Fukuoka Masahiro,Lord Sally,Marschner Ian,Tu Yu-Kang,Gralla Richard J.,Gebski Val,Mok Tony,Yang James Chih-Hsin

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/109/6/djw279/17856030/djw279.pdf

Reference26 articles.

1. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: Analyses from the phase III, randomized, open-label, ENSURE study;Ann Oncol.,2015

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial;Lancet Oncol.,2012

3. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;N Engl J Med.,2009

4. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR;N Engl J Med.,2010

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study;Lancet Oncol.,2011

Cited by 203 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The combined inhibition of SLC1A3 and glutaminase in osimertinib-resistant EGFR mutant cells;Biochimica et Biophysica Acta (BBA) - General Subjects;2024-10

2. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development;Cancer Treatment Reviews;2024-09

3. Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review;Frontiers in Oncology;2024-08-09

4. Treatment sequences in EGFR mutant advanced NSCLC;Lung Cancer;2024-08

5. Heterogeneity in PD-L1 expression between primary and metastatic lymph nodes: a predictor of EGFR-TKI therapy response in non-small cell lung cancer;Respiratory Research;2024-06-05